Literature DB >> 872080

Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.

C Fenselau, M N Kan, S S Rao, A Myles, O M Friedman, M Colvin.   

Abstract

Aldophosphamide (NSC 254), a putative key metabolite of cyclophosphamide, has now been isolated as a cyanohydrin derivative from an incubation mixture of cyclophosphamide with mouse liver microsomes in vitro and from the plasma of a cyclophosphamide-treated patient. The cyanohydrin has been shown to be identical with an authenic synthetic sample by mass spectrometry and combined gas chromatography-mass spectrometry.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 872080

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  28 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Proton magnetic resonance studies of the decomposition of 4-hydroxycyclophosphamide, a microsomal metabolite of cyclophosphamide.

Authors:  E J Valente; K K Chan; K L Servis
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

3.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

Review 4.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

5.  In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging.

Authors:  R H Peters; C S Brandon; L A Avila; O M Colvin; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide).

Authors:  D S Alberts; J G Einspahr; R Struck; G Bignami; L Young; E A Surwit; S E Salmon
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

8.  Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  The disposition of cyclophosphamide in a group of myeloma patients.

Authors:  V Bramwell; R T Calvert; G Edwards; H Scarffe; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.